Cyclerion appoints Michael Higgins and Dina Katabi to Board of Directors; board expands to six members.

Cyclerion Therapeutics, Inc.

Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.
Higgins appointed Audit Committee Chair; Katabi appointed to Nominating and Corporate Governance Committee.
Higgins is Voyager Therapeutics Chairman and former Ironwood COO; Katabi is MIT professor, MacArthur Fellow, and co-founder of Emerald Innovations.
Compensation: each receives $12,000 cash retainer and 20,000 restricted stock units vesting over 42 months.
Press release signals board refresh to explore possible licenses, mergers, acquisitions, or other investments.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Higgins

Director

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2023-11-30
Filed: December 1, 2023, 6:59 PM ET

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.

Appointed

Dina Katabi

Director

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2023-11-30
Filed: December 1, 2023, 6:59 PM ET

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Higgins was elected as Director at Cyclerion Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dina Katabi was elected as Director at Cyclerion Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.

View on SEC.gov

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-286790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.